Fifth disease that Dupixent has demonstrated positive pivotal results.... Jul 29
Atopic dermatitis is a chronic inflammatory disease of the skin that can be debilitating, and severe disease can significantly impact many aspects of life for ... Nov 30
These data reinforce the well-established long-term safety profile of Dupixent in moderate-to-severe atopic dermatitis.... Oct 29
New late-breaking data showing additional improvements in disease severity and extent at the microscopic level ... Oct 26
Dupixent combined with TCS in children aged 6 to 11 years with severe atopic dermatitis that is uncontrolled on topical prescription therapies... Oct 16
A pivotal Phase 3 trial of Dupixent met its primary and all key secondary endpoints in children aged 6 to 11 years with uncontrolled moderate-... Oct 13
The FDA granted evinacumab breakthrough therapy designation in 2017 for the treatment of hypercholesterolemia in patients with HoFH... Aug 13
-Advertisements-
Wednesday, May 15, 2024
.jpeg)
